Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-03-08
2011-03-08
Kolker, Daniel E (Department: 1649)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S017700, C514S009700
Reexamination Certificate
active
07902156
ABSTRACT:
The invention relates to improvements in the field of drug delivery. More particularly, the invention relates to polypeptides derived from aprotinin and from aprotinin analogs as well as conjugates and pharmaceutical compositions comprising these polypeptides or conjugates. The present invention also relates to the use of these polypeptide for transporting a compound or drug across the blood-brain barrier of a mammal and in the treatment and diagnosis of neurological diseases.
REFERENCES:
patent: 4671958 (1987-06-01), Rodwell et al.
patent: 4801575 (1989-01-01), Pardridge
patent: 4902505 (1990-02-01), Pardridge et al.
patent: 4942184 (1990-07-01), Haugwitz et al.
patent: 5028697 (1991-07-01), Johnson et al.
patent: 5041424 (1991-08-01), Saulnier et al.
patent: 5118668 (1992-06-01), Auerswald et al.
patent: 5169933 (1992-12-01), Anderson et al.
patent: 5258499 (1993-11-01), Konigsberg et al.
patent: 5578451 (1996-11-01), Nishimoto
patent: 5627270 (1997-05-01), Kahne et al.
patent: RE35524 (1997-06-01), Saulnier et al.
patent: 5683694 (1997-11-01), Bagshawe et al.
patent: 5780265 (1998-07-01), Dennis et al.
patent: 5807980 (1998-09-01), Lasters et al.
patent: 5869045 (1999-02-01), Hellstrom et al.
patent: 5922754 (1999-07-01), Burchett et al.
patent: 5948888 (1999-09-01), de la Monte et al.
patent: 5955444 (1999-09-01), Ingram et al.
patent: 5962266 (1999-10-01), White et al.
patent: 5981564 (1999-11-01), Pagé et al.
patent: 6093692 (2000-07-01), Shen et al.
patent: 6126965 (2000-10-01), Kasid et al.
patent: 6191290 (2001-02-01), Safavy
patent: 6245359 (2001-06-01), Milstein et al.
patent: 6306993 (2001-10-01), Rothbard et al.
patent: 6316024 (2001-11-01), Allen et al.
patent: 6348207 (2002-02-01), Milstein et al.
patent: 6376648 (2002-04-01), White et al.
patent: 6475481 (2002-11-01), Talmadge
patent: 6475781 (2002-11-01), Mercola et al.
patent: 6495513 (2002-12-01), Rueger et al.
patent: 6613890 (2003-09-01), White et al.
patent: 6660525 (2003-12-01), Martin et al.
patent: 6713454 (2004-03-01), Ekwuribe et al.
patent: 6906033 (2005-06-01), White et al.
patent: 6930090 (2005-08-01), Ekwuribe et al.
patent: 7019123 (2006-03-01), Tamburini et al.
patent: 7049058 (2006-05-01), Singh
patent: 7115707 (2006-10-01), Ben-Sasson et al.
patent: 7153946 (2006-12-01), McChesney et al.
patent: 7208174 (2007-04-01), Huwyler et al.
patent: 7557182 (2009-07-01), Beliveau et al.
patent: 7569544 (2009-08-01), Zankel et al.
patent: 7700554 (2010-04-01), Beliveau et al.
patent: 2003/0129186 (2003-07-01), Beliveau et al.
patent: 2004/0077540 (2004-04-01), Quay
patent: 2004/0146549 (2004-07-01), Ben-Sasson et al.
patent: 2004/0220132 (2004-11-01), Kaemmerer
patent: 2005/0042227 (2005-02-01), Zankel et al.
patent: 2005/0058702 (2005-03-01), Ben-Sasson et al.
patent: 2005/0100986 (2005-05-01), Verma et al.
patent: 2005/0178395 (2005-08-01), Hunter et al.
patent: 2005/0183731 (2005-08-01), Hunter et al.
patent: 2006/0182684 (2006-08-01), Beliveau
patent: 2006/0251713 (2006-11-01), Ben-Sasson et al.
patent: 2007/0149444 (2007-06-01), Laakkonen et al.
patent: 2007/0167365 (2007-07-01), Beliveau et al.
patent: 2007/0172462 (2007-07-01), Bohn et al.
patent: 2007/0197460 (2007-08-01), Fougerolles et al.
patent: 2008/0199436 (2008-08-01), Sawada
patent: 2009/0016959 (2009-01-01), Beliveau et al.
patent: 2009/0082277 (2009-03-01), Beliveau et al.
patent: 2009/0246211 (2009-10-01), Henri et al.
patent: 2010/0256055 (2010-10-01), Castaigne et al.
patent: 2283474 (1998-09-01), None
patent: 2525236 (2005-01-01), None
patent: 2637893 (2007-07-01), None
patent: 2638034 (2007-07-01), None
patent: 19953696 (2001-05-01), None
patent: 0393431 (1990-04-01), None
patent: WO 87/05702 (1987-09-01), None
patent: WO 96/31531 (1996-10-01), None
patent: WO96/35788 (1996-11-01), None
patent: WO 96/39183 (1996-12-01), None
patent: WO 96/40210 (1996-12-01), None
patent: WO97/33996 (1997-09-01), None
patent: WO 97/40854 (1997-11-01), None
patent: WO 00/01417 (2000-01-01), None
patent: WO 01/30319 (2001-05-01), None
patent: WO 02/33090 (2002-04-01), None
patent: WO 03/009815 (2003-02-01), None
patent: WO2004/060403 (2004-07-01), None
patent: WO 2005/002515 (2005-01-01), None
patent: WO 2006/086870 (2006-08-01), None
patent: WO 2007/009229 (2007-01-01), None
patent: WO 2007/020085 (2007-02-01), None
patent: WO2007/030619 (2007-03-01), None
patent: WO 2008/012629 (2008-01-01), None
patent: WO 2008/046228 (2008-04-01), None
patent: WO 2008/144919 (2008-12-01), None
patent: WO2009/039188 (2009-03-01), None
patent: WO2009/070597 (2009-06-01), None
patent: WO 2009/079790 (2009-07-01), None
patent: WO 2009/127072 (2009-10-01), None
patent: WO 2010/043047 (2010-04-01), None
patent: WO 2010/043049 (2010-04-01), None
patent: WO 2010/063122 (2010-06-01), None
patent: WO 2010/063123 (2010-06-01), None
patent: WO 2010/063124 (2010-06-01), None
patent: WO 2010/069074 (2010-06-01), None
International Search Report, PCT/CA2005/001158, mailed from the Canadian Intellectual Property Office on Nov. 15, 2005 (5 pgs.).
International Preliminary Report on Patentability, PCT/CA2005/001158, mailed from the Canadian Intellectual Property Office on Jul. 13, 2007, (26 pgs.).
Written Opinion of the International Searching Authority, PCT/CA2005/001158, mailed from the Canadian Intellectual Property Office on Nov. 15, 2005 (6 pgs.).
Ballabh et al., “The Blood-Brain Barrier: An Overview Structure, Regulation, and Clinical Implications,”Neurobiol Dis. 16:1-13 (2004).
Bickel et al., “Delivery of Peptides and Proteins Through the Blood-Brain Barrier,”Adv Drug Deliv Rev. 46:247-279 (2001).
Boado, “Blood-brain Barrier Transport of Non-viral Gene and RNAi Therapeutics,”Pharm Res. 24:1772-1787 (2007).
Bork, “Powers and Pitfalls in Sequence Analysis: The 70% Hurdle,”Genome Res. 10:398-400 (2000).
Bork et al., “Go Hunting in Sequence Databases But Watch Out for the Traps,”Trends Genet. 12:425-427 (1996).
Brenner, “Errors in Genome Annotation,”Trends Genet. 15:132-133 (1999).
Castex et al., “2-Pyrrolinodoxorubicin and Its Peptide-vectorized Form Bypass Multidrug Resistance,”Anticancer Drugs. 15:609-617 (2004).
Coon et al., “Solutol HS 15, Nontoxic Polyoxyethylene Esters of 12-hydroxystearic Acid, Reverses Multidrug Resistance,”Cancer Res. 51:897-902 (1991).
D'Onofrio et al., “Glycomimetics as Decorating Motifs for Oligonucleotides: Solid-phase Synthesis, Stability, and Hybridization Properties of Carbopeptoid-oligonucleotide Conjugates,”Bioconjug Chem. 16:1299-1309 (2005).
Dagenais et al., “Development of an In Situ Mouse Brain Perfusion Model and Its Application to mdr1a P-glycoprotein-deficient Mice,”J Cereb Blood Flow Metab. 20:381-386 (2000).
Deane et al., “LRP/Amyloid β-Peptide Interaction Mediates Differential Brain Efflux of Aβ Isoforms,”Neuron. 43:333-344 (2004).
Dehouck et al., “A New Function for the LDL Receptor: Transcytosis of LDL Across the Blood-Brain Barrier,”J Cell Biol. 138:877-889 (1997).
Dehouck et al., “An Easier, Reproducible, and Mass-production Method to Study the Blood-brain Barrier in Vitro,”J Neurochem. 54:1798-1801 (1990).
Dehouck et al., “Drug Transfer Across the Blood-Brain Barrier: Correlation Between In Vitro and In Vivo Models,”J Neurochem. 58:1790-1797 (1992).
Demeule et al., “High Transcytosis of Melanotransferrin (P97) Across the Blood-Brain Barrier,”J Neurochem. 83:924-933 (2002).
Demeule et al., “Identification and Design of Peptides As a New Drug Delivery System For the Brain,”J Pharmacol Exp Ther. 324:1064-1072 (2008).
Demeule et al., “Isolation of Endothelial Cells from Brain, Lung, and Kidney: Expression of the Multidrug Resistance P-Glycoprotein Isoforms,”Biochem Biophys Res Commun. 281:827-834 (2001).
Doerks et al., “Protein Annotation: Detective Work for Function Prediction,”Trends Genet. 14:248-250 (1998).
Fillebeen et al., “Receptor-Mediated Transcytosis
Beliveau Richard
Ché Christian
Demeule Michel
Regina Anthony
Angiochem Inc.
Bieker-Brady Kristina
Clark & Elbing LLP
Kolker Daniel E
LandOfFree
Aprotinin polypeptides for transporting a compound across... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aprotinin polypeptides for transporting a compound across..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aprotinin polypeptides for transporting a compound across... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2783367